Phibro Animal Health
PAHC on Nasdaq. Phibro Animal Health sells animal medicines and feed minerals to farmers and veterinarians. Market value $764m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to June 2026.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $0.66 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns 10 cents a year. Above 10 is good.
Quality score: 66 of 100. Price score: 53 of 100. Our list needs 70 on quality and 60 on price.
$36.61 a share, 30% above its 1-year low
Over the past year the price has ranged from $28.25 to $60.08.
Dividend: 1.3% a year
Paid every year for at least 5 years
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $942m | $978m | $1.0bn | $1.3bn | $1.5bn |
| Operating margin | |||||
| Operating margin | 8.4% | 7.3% | 5.2% | 8.5% | 12.8% |
| Debt to equity | |||||
| Debt to equity | 1.10 | 1.18 | 1.22 | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.04bn | 0.04bn | 0.04bn |
Health checks
- Free cash flow positive3 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsStrong, 12.7% a year
- Buying back its own sharesRoughly flat
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $397 million last quarter, up 5% on a year ago.
- Profit: $22 million, up 26% on a year ago.
- It keeps 13 cents of each $1 of sales as operating profit, up from 9 cents a year earlier.
- Spare cash over the past 12 months: $10 million, down from $42 million.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $260m |
| December 2024 | $309m |
| March 2025 | $348m |
| June 2025 | $379m |
| September 2025 | $364m |
| December 2025 | $374m |
| March 2026 | $384m |
| June 2026 | $397m |
| Quarter to | Amount |
|---|---|
| September 2024 | $7m |
| December 2024 | $3m |
| March 2025 | $21m |
| June 2025 | $17m |
| September 2025 | $27m |
| December 2025 | $27m |
| March 2026 | $24m |
| June 2026 | $22m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 August 2026
- Next quarterly (estimated, 10-Q)
- 5 August 2026
Who owns it
1 long-term investor we follow owns it, down from 2 last quarter. 208 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| LSV Asset ManagementJosef Lakonishok | $4m | <0.1% | Cut |
Sold out this quarter
- Polen CapitalDan DavidowitzSold out
Largest holders overall
- BlackRock$101m
- FMR$99mAdded
- State Street$33mAdded
- Millennium Management$29mAdded
- Vanguard Capital Management$29mAdded
- Geode Capital Management$21mAdded
- Lord, Abbett$21mAdded
- Dimensional Fund Advisors LP$17mAdded
- Vanguard Portfolio Management$16mAdded
- Renaissance Technologies$15mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
7 investors own more than 5%.
- Jack C. BendheimInsider or founder49.3%−0.6 ptsSince 11 December 2025
What they said
Item 4 of the Schedule 13D is hereby supplemented as follows: On December 11, 2025, BFI Co., LLC ("BFI") entered into a Rule 10b5-1 sales plan (the "Sales Plan") with Goldman, Sachs & Co. LLC ("Broker") pursuant to which Broker is authorized and directed to sell on behalf of BFI…
Read the filing - BFI Co., LLCPassive investorat least 48.2%−0.1 pts(filed with 1 related holder)Since 20 May 2026
What they said
Item 4 of the Schedule 13D is hereby supplemented as follows: On May 20 2026, BFI entered into a Rule 10b5-1 sales plan (the "Sales Plan") with Goldman, Sachs & Co. LLC ("Broker") pursuant to which Broker is authorized and directed to sell on behalf of BFI up to 750,000 shares…
Read the filing - BlackRock, Inc.Passive investor15.7%Since 31 March 2025
- FMR LLCPassive investorat least 15.0%+4.5 pts(filed with 1 related holder)Since 30 June 2026
- Millennium Management LLCPassive investorat least 5.1%(filed with 2 related holders)Since 23 July 2026
- Vanguard Capital ManagementPassive investor5.1%Since 31 March 2026
- Brandes Investment PartnersPassive investorat least 3.3%−7.2 pts(filed with 3 related holders)Since 31 December 2024
- Pzena Investment ManagementPassive investorSold down below 5%Since 31 March 2025
- Barclays PLCPassive investorSold down below 5%Since 31 March 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Jack C. Bendheim Insider or founder | 49.3%−0.6 pts | 11 December 2025 | What they saidItem 4 of the Schedule 13D is hereby supplemented as follows: On December 11, 2025, BFI Co., LLC ("BFI") entered into a Rule 10b5-1 sales plan (the "Sales Plan") with Goldman, Sachs & Co. LLC ("Broker") pursuant to which Broker is authorized and directed to sell on behalf of BFI… Read the filing |
BFI Co., LLC Passive investor | at least 48.2%−0.1 pts (filed with 1 related holder) | 20 May 2026 | What they saidItem 4 of the Schedule 13D is hereby supplemented as follows: On May 20 2026, BFI entered into a Rule 10b5-1 sales plan (the "Sales Plan") with Goldman, Sachs & Co. LLC ("Broker") pursuant to which Broker is authorized and directed to sell on behalf of BFI up to 750,000 shares… Read the filing |
BlackRock, Inc. Passive investor | 15.7% | 31 March 2025 | |
FMR LLC Passive investor | at least 15.0%+4.5 pts (filed with 1 related holder) | 30 June 2026 | |
Millennium Management LLC Passive investor | at least 5.1% (filed with 2 related holders) | 23 July 2026 | |
Vanguard Capital Management Passive investor | 5.1% | 31 March 2026 | |
Brandes Investment Partners Passive investor | at least 3.3%−7.2 pts (filed with 3 related holders) | 31 December 2024 | |
Pzena Investment Management Passive investor | Sold down below 5% | 31 March 2025 | |
Barclays PLC Passive investor | Sold down below 5% | 31 March 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $317,700 of shares on the open market. 1 sold $30m, $30m of it under preset trading plans.
- CORCORAN E THOMASDirectorBought
- Date
- 29 May 2026
- Shares
- 10,000
- Price
- $31.77
- Value
- $317,700
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 7 May 2026
- Shares
- 4,528
- Price
- $48.49
- Value
- $219,561
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 6 May 2026
- Shares
- 7,040
- Price
- $57.37
- Value
- $403,883
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 5 May 2026
- Shares
- 7,040
- Price
- $55.80
- Value
- $392,836
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 30 April 2026
- Shares
- 7,040
- Price
- $52.77
- Value
- $371,483
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 29 April 2026
- Shares
- 7,040
- Price
- $52.92
- Value
- $372,557
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 28 April 2026
- Shares
- 7,040
- Price
- $55.91
- Value
- $393,579
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 23 April 2026
- Shares
- 7,040
- Price
- $54.10
- Value
- $380,859
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 22 April 2026
- Shares
- 7,040
- Price
- $54.29
- Value
- $382,202
- BENDHEIM JACKPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 21 April 2026
- Shares
- 7,040
- Price
- $55.98
- Value
- $394,104
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 29 May 2026 | CORCORAN E THOMAS Director | Bought | 10,000 | $31.77 | $317,700 |
| 7 May 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 4,528 | $48.49 | $219,561 |
| 6 May 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $57.37 | $403,883 |
| 5 May 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $55.80 | $392,836 |
| 30 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $52.77 | $371,483 |
| 29 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $52.92 | $372,557 |
| 28 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $55.91 | $393,579 |
| 23 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $54.10 | $380,859 |
| 22 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $54.29 | $382,202 |
| 21 April 2026 | BENDHEIM JACK President and CEO, Director | Sold under a preset trading plan | 7,040 | $55.98 | $394,104 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Aug 2026, and no later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.